No

This debate will examine the evolving role of oral selective estrogen receptor degraders (SERDs) in breast cancer and address the question of whether these agents are truly interchangeable. Compare differences in mechanism of action, clinical efficacy, resistance profiles, and safety across available and emerging oral SERDs. Speakers will highlight implications for patient selection and sequencing in hormone receptor-positive disease and provide expert insight into how nuanced differences among oral SERDs may influence real-world treatment decisions. Our presenters will examine differences in pharmacology, potency, resistance profiles, and clinical trial outcomes among available and emerging agents, discussing how these distinctions may influence patient selection, sequencing, and combination strategies. Delve into the clinical relevance for patients of heterogeneity within the oral SERD class.